Translate AMICOR contents if you like

Friday, April 15, 2011

Biomarker May Predict Adverse Events in Afib

By Todd Neale, Staff Writer, MedPage Today
Published: April 14, 2011
Reviewed by Michael Mullen, MD; Clinical Instructor of Vascular Neurology, University of Pennsylvania and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

Elevated plasma levels of a marker of endothelial damage may be a risk factor for adverse cardiovascular events in anticoagulated patients with permanent atrial fibrillation, researchers found.

High levels of von Willebrand factor were associated with greater risks of all-cause mortality, major bleeding, and a composite of cardiovascular outcomes (P<0.05 for all), according to Gregory Lip, MD, of the University of Birmingham Center for Cardiovascular Sciences in Birmingham, England, and colleagues./.../

1 comment:

Dan Walter said...

I would caution those who are considering catheter ablation for afib to think twice. It is a corporate-driven procedure of dubious safety and effectiveness. If you do opt for it, do your research, find an experienced operator and avoid teaching hospitals.

All lessons learned the hard way: http://collateral-damage.net